

Books Received

The following books are presented here as a service to our readership to alert them of new titles and as a courtesy to those who have sent copies of these books to the Journal office.

Guns and Suicide: An American Epidemic, by Michael D. Anestis. Oxford University Press, 2018, 184 pp., \$29.95.

The 2×4 Model: A Neuroscience-Based Blueprint for the Modern Integrated Addiction and Mental Health Treatment System, by R. Andrew Chambers. Routledge, 2018, 288 pp., \$89.95 (paper).

Psychotherapy for a Democratic Mind, by Israel W. Charny. Lexington Books, 2017, 400 pp., \$120.00.

Nonlinear Psychoanalysis: Notes from Forty Years of Chaos and Complexity Theory, by Robert M. Galatzer-Levy. Routledge, 2018, 282 pp., \$41.26 (paper).

Ethics Challenges in Forensic Psychiatry and Psychology Practice, by Ezra E.H. Griffith. Columbia University Press, 2018, 376 pp., \$65.00.

Highest of Highs to Lowest of Lows: My Battle with Bipolar Disorder, by Michael Kinyanjui. EditPros LLC, 2018, 238 pp., \$7.58 (paper).

Radically Open Dialectical Behavior Therapy: Theory and Practice for Treating Disorders of Overcontrol, by Thomas R. Lynch. Context Press, 2018, 600 pp., \$59.95.

Aidan's Shadow, by Luke Norton. Luke Norton, 2017, 777 pp., \$14.00 (paper).

Mental Disorders Around the World: Facts and Figures from the WHO World Mental Health Surveys, by Kate M. Scott, Peter De Jonge, Dan J. Stein, and Ronald C. Kessler, eds. Cambridge University Press, 2018, 396 pp., \$135.00.

Indefinite Postponement: A Case Study of Adolescent Suicidality, by John P. Williams. Pressed Wafer, 2018, 87 pp., \$15.00 (paper).

Disclosure of Editors' Financial Relationships

The *American Journal of Psychiatry* requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:

Robert Freedman, M.D., reports no financial relationships with commercial interests.

David A. Lewis, M.D., currently receives investigator-initiated research support from Pfizer and serves as a consultant to Merck.

Robert Michels, M.D., reports no financial relationships with commercial interests.

Daniel S. Pine, M.D., reports no financial relationships with commercial interests.

A. John Rush, M.D., consulting fees from Akili, Brain Resource Inc., Compass Inc., CurbstoneConsultant LLC, Eli Lilly, Emmes Corp., John Peter Smith Healthcare, Liva-Nova, Mind Linc, Sunovion, Takeda USA, Taj Medical, UT Southwestern Medical Center at Dallas; speaking fees from Liva-Nova and Sing-Health; and royalties from Guilford Press and UT Southwestern, Dallas (for the Inventory of Depressive symptoms and its derivatives such as the QIDS-C). He is a named co-inventor on two patents: U.S. Patent No. 7,795,033 (Methods to Predict the Outcome of Treatment with Antidepressant Medication; Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS) and U.S. Patent No. 7,906,283 (Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication; Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S).

Susan K. Schultz, M.D., has received research support from the Alzheimer's Disease Cooperative Study for projects conducted in partnership with Toyama Chemical Company and in partnership with Eli Lilly and Company.

Carol A. Tamminga, M.D., has received research support from Sunovion and travel funds from Autiphony Therapeutics and has served as a consultant for Astellas, Eli Lilly, Kaye Scholer LLC for Pfizer, and Lundbeck.